To investigate whether everolimus inhibitory effects might involve growth factor activated pathways, cell viability was assessed in E-R MTC cultures treated with or without 50 nM IGF-I, in the presence or in the absence of 10 nM–1 μM everolimus. The gene discussed is IGF1; the disease is medullary thyroid gland carcinoma.